Each gene therapy contains either CNGB3 or CNGA3, based on the reasoning that mutations in these genes affect 80% of achromatopsia patients, and were packaged into an AAV capsid and then delivered by a subretinal injection after vitrectomy. Here, CNGA3 is linked to achromatopsia.